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Background: The success rate of infertility treatments remains modest. Endometrial injury has been suggested as
an intervention to increase the probability of pregnancy in women undergoing assisted reproductive technologies
such as in vitro fertilisation (IVF). The majority of studies and systematic reviews have reported that endometrial
injury improves the outcomes of IVF, intrauterine insemination and natural conception; however, the size and
quality of the studies are poor. The low quality of the available evidence questions the presence of any real
beneficial effect, and the applicability of the intervention in different populations remains unclear.
Methods/design: The PIP trials are three multi-centre, randomised controlled trials designed to test three separate
hypotheses: whether endometrial injury increases the probability of live birth in women or couples
1) who are undergoing autologous embryo transfer as part of an IVF cycle (PIP-IVF),
2) with unexplained infertility who are attempting to conceive naturally (PIP-UE) and
3) with subfertility related to polycystic ovarian syndrome (PCOS) who are on ovulation induction medication and
attempting to conceive (PIP-PCOS).
Participants will be randomised to either undergo endometrial injury by endometrial pipelle biopsy or to:
• no intervention (PIP-IVF), or
• a sham procedure (PIP-PCOS and PIP-UE).
In PIP-IVF, endometrial injury will be carried out between day three of the cycle prior to the IVF cycle, and day three
of the IVF cycle. In PIP-UE and PIP-PCOS, endometrial injury or a sham procedure will be undertaken between days
1–12 of a menstrual cycle or ovulation induction cycle respectively. Participants in PIP-UE and PIP-PCOS will then be
followed for three cycles during which time they will attempt to conceive from sexual intercourse. To ensure
allocation concealment, randomisation will be carried out using a web-based system or sequentially numbered,
opaque, sealed envelopes. The primary outcome is live birth. Secondary outcomes include ongoing pregnancy,
clinical pregnancy and miscarriage.
The required sample sizes for the PIP studies have been estimated at 840 (PIP-IVF), 350 (PIP-UE) and 280 (PIP-PCOS).
Primary analysis will be as per intention-to-treat principles.
Discussion: The PIP trials are designed to address the gaps in the utility of endometrial scratching as a treatment
for subfertility in three different populations. If the beneficial effect of this intervention can be confirmed in these
settings, endometrial scratching will provide a cost-effective method for helping women and couples to conceive.
Trial registrations: PIP-IVF ACTRN12614000626662 registered 13/6/2014; PIP-PCOS ACTRN12614000657628
registered 24/6/2014; PIP-UE ACTRN12614000656639 registered 24/6/2014. The trials are ongoing.
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Having a baby is an important goal for many couples.
Unfortunately, up to 10 % of couples will not achieve
pregnancy after a year of frequent, unprotected inter-
course and are defined as being subfertile [1]. Many sub-
fertile couples seek fertility treatments to help them
conceive. However, even the most successful fertility
treatment, in vitro fertilisation (IVF), has a live birth rate
of only 30 % per cycle [2, 3]. Failure of an IVF cycle to
result in pregnancy can be due to a number of factors
and, even when high quality embryos are replaced,
implantation rates remain modest. A lack of adequate
endometrial receptivity is thought to be responsible for
up to two-thirds of unsuccessful embryo transfers [4].
Endometrial injury is currently being proposed as a
technique to improve the endometrial receptivity and in
turn the probability of conception in IVF cycles. Endo-
metrial biopsy is the most common procedure used to
deliver an endometrial injury [5]. The procedure involves
the insertion of a catheter, such as a pipelle sampler,
through the cervix and into the uterus, where a sample
of the endometrium is obtained via light suction and
rotation within the uterine cavity. The biopsy results in a
‘scratch’ or ‘injury’ to the endometrium during the
process of obtaining a sample. Outside of the fertility area,
pipelle biopsy is routinely performed to collect endomet-
rial samples for diagnostic purposes, for example, in
women with abnormal menstrual bleeding. It is a well-
tolerated procedure with a proven safety profile [6, 7].
In 2000 it was first reported in a retrospective study
that 11 of 12 women who had undergone a series of
investigational endometrial biopsies conceived in their
subsequent IVF cycle [8]. A prospective non-randomised
study by the same research group reported that women
allocated to endometrial biopsy in the cycle prior to IVF
cycle were twice as likely to conceive as women who had
not [9]. Several studies have since investigated the appar-
ent beneficial effect of endometrial injury in IVF cycles,
and although there is substantial heterogeneity in the
study designs and participant populations, a recent
Cochrane review including randomised controlled trials
(RCTs) reports an increase in the probability of preg-
nancy and live birth following endometrial sampling in
the cycle preceding embryo transfer (RR = 1.34, 95 % CI
1.21–1.61 and RR = 1.42, 95 % CI 1.08–1.85, respect-
ively) [5]. Other reviews and meta-analyses which have
included both RCTs and non-randomised studies have
similar conclusions [10–12]. The effect appears to be the
most pronounced in women who have repeatedly failed
to achieve a pregnancy after multiple embryo transfers,
that is, women with recurrent implantation failure (RIF)
[13]. Note that in the only study where endometrial
injury was performed on the day of oocyte retrieval, a
detrimental effect on pregnancy rate was observed [14].Almost all of the RCTs assessing endometrial injury
are associated with significant limitations that place
them at a high risk of bias, which is known to be associ-
ated with exaggerated effect estimates (such as lack of
adequate blinding and allocation concealment, high rates
of participant attrition), or raise questions regarding the
generalisability of results (such as use of multiple embryo
transfer policies or ovulation induction medications in
couples with unexplained infertility, timing of endometrial
injury, and the device used for causing endometrial in-
jury). Another common issue in a number of the studies is
the potential exposure of the control group to uninten-
tional endometrial injury resulting from a placebo proced-
ure [15–17] or a co-intervention such as hysteroscopy,
either prior to study enrolment [18] or simultaneously
with the study procedure [19, 20]. Finally, only a small
proportion of the studies reported live birth, arguably the
most important outcome for both clinicians and subfertile
couples.
The mechanism by which endometrial injury may
increase the probability of conception has been the topic
of a number of studies and speculations, and is extensively
summarised in recent reviews [10, 21]. The most fre-
quently cited theory is that of inflammation. Endometrial
scratching has been shown to induce an inflammatory re-
sponse in the endometrium, which is believed to mediate
the dialogue between the endometrium and the blastocyst
and facilitate the process of implantation [22]. The result-
ant inflammatory response involves the production of
inflammatory cytokines and subsequent recruitment of
macrophages and other immune cells, factors known to
be present during the window of implantation. This hy-
pothesis is supported by repeat biopsy studies, in which
women who had undergone a second biopsy had in-
creased levels of cytokines such as TNF-α and MIP-1B,
and other molecules known to be associated with implant-
ation, such as osteopontin [22–25]. It is possible that
endometrial injury may also be beneficial in women with
unexplained infertility or polycystic ovarian syndrome
(PCOS) who are trying to conceive from sexual inter-
course; conditions of infertility in which poor endometrial
receptivity has been implicated [26–30].
Due to the generally poor quality of the published
studies and a lack of a clear understanding regarding the
underlying mechanism of effect, the reproductive benefit
of endometrial injury remains controversial [5, 31–34].
This protocol describes studies to be undertaken in three
separate groups of women in whom inadequate endo-
metrial receptivity may be partly responsible for the ex-
perienced infertility: unexplained infertility, PCOS and
women undergoing embryo transfer as part of an IVF/
intracytoplasmic sperm injection (ICSI) cycle.
Endometrial biopsy is a simple, cheap and well-tolerated
procedure which can be performed without anaesthetic in
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cost-effective method for increasing the probability of
pregnancy and live birth in women or couples who are
undergoing IVF or who are trying to conceive naturally or
with ovulation induction.
Research questions
The Pipelle for Pregnancy (PIP) studies will evaluate
whether endometrial injury delivered by an endometrial
pipelle biopsy procedure increases the probability of live
birth in
1) Women undergoing autologous embryo transfer;
a fresh transfer as part of an IVF cycle or a
frozen-thaw embryo transfer (PIP-IVF)
2) Couples with unexplained infertility attempting to
conceive spontaneously (PIP-UE)
3) Couples with subfertility associated with
polycystic ovarian syndrome who are on
ovulation induction medication and trying to
conceive (PIP-PCOS).
Methods/design
The PIP studies are pragmatic, parallel, multi-centre,
superiority RCTs.
The pragmatic nature of the studies is a result of
the broad inclusion criteria, time frame in which the
intervention is administered and lack of restriction to
specific stimulation or ovulation induction protocols.
This rationale is based on the existing evidence in
favour of endometrial scratching before IVF, in which
a benefit has been shown across a range of time
frames for performing the intervention and in differ-
ent patient populations. Inclusion of a heterogeneous
population in a large study provides an opportunity
to detect treatment effects within different patient
subgroups.
Blinding
PIP-IVF is an open label study; women will be aware of
their study allocation as they will be randomised to
undergo either endometrial biopsy or no procedure.
PIP-PCOS and PIP-UE are single-blind studies; women
will not be aware of their study allocations as they will be
randomised to either an endometrial biopsy or a sham
procedure (placement of the pipelle in the anterior
fornix).
In all three studies, the doctor performing the pro-
cedure will necessarily be aware of the participant’s
allocation.
Outcomes
The primary outcome is live birth rate per woman rando-
mised, as defined previously [35].Secondary outcomes include:
 ongoing pregnancy per woman randomised
(defined as continuing pregnancy
diagnosed by ultrasonographic visualisation
of one or more gestational sacs on or after
12 weeks gestation)
 clinical pregnancy per women randomised
(defined as a pregnancy diagnosed by
ultrasonographic visualisation of one or more
gestational sacs, including ectopic pregnancy)
 biochemical pregnancy (defined as βhcg > 25 mIU/ml)
PIP-IVF only
 multiple pregnancies per women randomised and
per clinical pregnancy (defined as ultrasonographic
visualisation of two or more gestational sacs or
heartbeats)
 ectopic pregnancy per women randomised
and per clinical pregnancy (defined as a
pregnancy in which implantation takes place
outside the uterine cavity)
 miscarriage per women randomised and per clinical
pregnancy (defined as the spontaneous loss of a
clinical pregnancy before 20 completed weeks of
gestational age)
 neonatal characteristics (for example, gender,
gestation at birth, malformations)
 placenta characteristics (placenta previa:
major, placenta previa: minor, placental
abruption, placenta accreta: previous
uterine surgery, placenta accreta: no previous
uterine surgery)
 pain during the procedure (as measured by a 10 cm
visual analogue scale (VAS))
 bleeding the day following the procedure.Eligibility criteria
Inclusion criteria
Women who meet the following inclusion criteria are
eligible to take part in the PIP studies:PIP-IVF
1. Planning to undergo autologous embryo transfer
Fertility clinics that routinely perform single embryo
transfers are eligible to recruit for the PIP-IVF study. As
per the pragmatic nature of the PIP studies, a number of
women undergoing double embryo transfers will be re-
cruited. The proportion of women in PIP-IVF who are
undergoing double embryo transfers should not exceed
the normal proportion of women who undergo double
embryo transfers at the participating clinics (no more
than 20 % [3]).
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1. In a relationship where the couple is having regular,
unprotected sexual intercourse and pregnancy is
desired
2. 42 years of age or younger at the time of
randomisation
3. Diagnosed with unexplained infertility, must meet
all of:
a) Unsuccessfully trying to conceive for at least
12 months,
b) Normal ovulation (21–42 day menstrual cycles
with variation <8 days),
c) Male partner has had a normal semen analysis in
the last five years according to WHO criteria [36]
(volume ≥1.5 ml, progressive motility ≥32 %,
concentration ≥15 million/ml) or total motile
count >10 million
4. Have either:
a) Two ovaries and two probably patent fallopian
tubes (normally confirmed by laparoscopy or
hysterosalpingography (HSG))
b) A previous intrauterine pregnancy, and no
subsequent surgery, infection or ectopic
pregnancy that may reduce tubal patency
5. Body mass index (BMI) ≤ 35 kg/m2
6. Willing and able to have regular sexual intercourse
in the cycle in which the procedure is performed,
and for two cycles following the procedure.
PIP-PCOS
1. In a relationship where the couple is having regular,
unprotected sexual intercourse and pregnancy is
desired
2. 42 years of age or younger at the time of
randomisation
3. Meet the Rotterdam criteria for PCOS, at least two
of the following [37]:
a) Oligoovulation or anovulation (confirmed by
luteal phase progesterone test or history of
irregular cycles)
b) Excess androgen activity (elevated serum
testosterone or clinical signs such as excess hair)
c) Polycystic ovaries (as evidenced on ultrasound)
4. Male partner has had a normal semen analysis in
the last five years according to WHO criteria [36]
(volume ≥1.5 ml, progressive motility ≥32 %,
concentration ≥15 million/ml) or total motile
count >10 million
5. Have either
a) Two ovaries and two probably patent fallopian
tubes (normally confirmed by laparoscopy or HSG)
b) A previous intrauterine pregnancy, and no
subsequent surgery, infection or ectopic
pregnancy that may reduce tubal patencyc) Confirmed to have ovulated in a total of six or
fewer ovulation induction cycles (as assessment of
tubal patency may not be recommended until
failure to achieve pregnancy following a number
of cycles of successful ovulation)
6. Body mass index (BMI) ≤ 35 kg/m2
7. Willing and able to have regular sexual
intercourse in the cycle in which the procedure is
performed, and for two cycles following the
procedure
8. Planning to undergo at least three consecutive cycles
of ovulation induction (unless pregnancy occurs
prior to completion of three study cycles).
Exclusion criteria
Women who meet the following exclusion criteria are
not eligible to take part in the PIP studies:
PIP-IVF, PIP-PCOS and PIP-UE
1. Have had any disruptive instrumentation within
the uterine cavity (for example, hysteroscopy,
hysterosalpingography, laparoscopy, surgically
managed miscarriage or endometrial biopsy)
within three months prior to day one of the
planned embryo transfer cycle/menstrual cycle/
ovulation induction cycle, or planning to undergo
a procedure involving disruptive instrumentation
at any stage during the study. Embryo transfer
and intrauterine insemination (IUI) procedures are
not considered to cause disruptive
instrumentation
2. Entered previously into this study or participated in
another trial in the last 30 days
3. Any contraindication to endometrial biopsy and/
or being pregnant and/or carrying a pregnancy to
term.
Additional exclusion criteria for PIP-UE
4. On ovulation induction medication or any other
fertility treatment or planning any fertility treatment
during the study period
5. Have had a miscarriage in the last 12 months or
have moderate or severe endometriosis (grade 3 or 4)
and therefore do not meet the criteria for unexplained
infertility [38]
6. Have recurrent miscarriage (spontaneous loss of
three or more clinical pregnancies [39]).
Additional exclusion criteria for PIP-PCOS
1. The presence of any other cause of infertility,
where spontaneous conception is unlikely
(for example, large fibroids, moderate or severe
endometriosis (grade 3 or 4) or severe male
factor)
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three or more clinical pregnancies [39])
Standard care
Standard care will be identical in both arms of each PIP
study. The PIP studies are pragmatic trials, and standard
care may differ slightly between participating centres.
For example, some centres may prefer an antagonist
protocol and others may prefer a long course agonist
protocol for IVF cycles.
Participants in PIP-IVF are either taking part in an
IVF/ICSI cycle involving controlled ovarian stimula-
tion, oocyte collection and fresh embryo transfer, or
are planning a frozen-thaw embryo transfer. Any IVF
protocol or use of additional treatments, such as pre-
implantation genetic diagnoses or assisted hatching,
is acceptable. Similarly, artificial, manufactured and
natural cycles for frozen-thaw embryo transfers are
acceptable.
PIP-PCOS participants are on ovulation induction
medication: clomiphene, letrozole, follicle-stimulating
hormone (FSH) or metformin. The choice of medica-
tions, dosages and combinations of medications may
vary.
Participants in PIP-UE should not be on any fertility
treatment. Participants in PIP-PCOS and PIP-UE are
asked not to undergo any additional fertility treatment;
for example, IUI and IVF are considered protocol viola-
tions. Vitamins, dietary supplements and other medica-
tions or procedures which are not normally considered
fertility treatments, such as acupuncture, are permitted
in all studies.Table 1 Schedule of procedures and outcome measurements for PI
Pre-study Day 1 of
prior cycle
Day 3 of prior cycle-d
3 of IVF/embryo
transfer cycle
Eligibility screen x
Informed consent x
Randomisation x
Endometrial scratching
(intervention group only)
x
Pain (VAS) (intervention
group only)
x
Adverse events
(intervention group only)
x
Bleeding (intervention
group only)
IVF cycle characteristics
Biochemical pregnancy
Clinical pregnancy
Ongoing pregnancy
Live birthEligibility assessment
Potentially eligible women will be informed about the PIP
study by invitation letter, advertisement (for example, pos-
ter or newsletter) or their treating clinician or nurse. All
potential participants will have the opportunity to ask
questions about the study and discuss any concerns or
queries prior to making a decision about whether to take
part. Informed consent will be obtained from all par-
ticipants in writing prior to their recruitment. In-
formed consent will be undertaken by a PIP study
researcher who is familiar with the study details and
has adequate training and experience in trial recruit-
ment (see Tables 1 and 2).
The details of all women assessed for eligibility will be
recorded to ensure reporting as per the CONSORT
statement [40]. This record will include reasons for ineli-
gibility or nonparticipation.
Randomisation
A third-party, Internet-based, data collection and ran-
domisation system will be used to confirm participant
eligibility and ensure allocation concealment; that is,
participant allocations are concealed within the system
until the patient is randomised. Only participants who
meet the eligibility criteria can be randomised. In
instances where computer or Internet access is not reli-
able, participants will be randomised using sequentially
numbered, opaque, sealed envelopes. Dedicated PIP
study personnel will be responsible for randomising par-
ticipants at each site. Participants will be randomised in
a 1:1 ratio using block randomisation of two different
sizes between 5–15 repeating in random order, stratifiedP-IVF
ay Day after
procedure
IVF cycle/
embryo
transfer
About 2 weeks
after embryo
transfer
About
6 weeks
gestation
≥12 weeks
gestation
Birth
x
x
x
x
x
x
x
Table 2 Schedule of procedures and outcome measurements for PIP-UE and PIP-PCOS
Pre-study Day 1-12 of
cycle 1
Day after
procedure day
End of study/end
of cycle 3
About 6 weeks
gestation
≥12 weeks
gestation
Birth
Eligibility screen x
Informed consent x
Randomisation x
Study intervention x
Pain (VAS) x
Adverse events x x
Bleeding x
Cycle characteristics (e.g., intercourse frequency,
ovulation medication dose (PIP-PCOS only),
via study diary)
x
Clinical pregnancy x
Ongoing pregnancy x
Live birth x
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transfer (the latter in PIP-IVF only).Timing of randomisation and the study procedure
PIP-IVF In PIP-IVF, eligible women will be randomised
to the study on or after day one of the cycle that pre-
cedes the embryo transfer cycle (Table 1). For example,
in participants scheduled for a long course buserelin
cycle, randomisation will ideally take place on day one of
the cycle, 21 days before down-regulation begins.
Women will be informed of their allocation immediately
after randomisation. Women randomised to the proced-
ure group will be scheduled to undergo an endometrial
biopsy procedure between day three of the cycle preced-
ing embryo transfer and the third day of the embryo
transfer cycle. Day one of the embryo transfer cycle is
defined as either the day before the first day of con-
trolled ovarian stimulation or day one of a menstrual
period/withdrawal bleed for frozen-thaw embryo transfer
cycles.
The large window of opportunity to perform the endo-
metrial biopsy procedure is based on results from previ-
ous studies. Endometrial injury has been reported to
have a beneficial effect as early as the menstrual period
of the cycle preceding embryo transfer [20], and as late
as the menstrual period following down-regulation [41].
This flexibility is also in keeping with the pragmatic na-
ture of these studies.PIP-PCOS and PIP-UE Women who are eligible for
PIP-UE or PIP-PCOS will be scheduled for the proced-
ure between days one and 12 of a menstrual cycle (PIP-
UE) or ovulation induction cycle (PIP-PCOS). The
women will be randomised once they arrive at the clinic,allocating them to either undergo the endometrial bi-
opsy or a sham procedure (Table 2).
The rationale behind timing the study procedure dur-
ing the follicular phase of the cycle is threefold. Firstly,
there is some concern that performing an intrauterine
procedure in the luteal phase may disrupt a newly im-
planted embryo and therefore reduce the chance of
pregnancy. Secondly, women would need to be asked to
avoid conceiving during the pipelle biopsy cycle, and this
would reduce the women’s overall opportunity to con-
ceive. Lastly, it is thought that the endometrial biopsy
procedure may be less uncomfortable and less likely to
be abandoned due to inability to pass the pipelle if per-
formed during the menstrual period, as the cervical
canal is slightly more open. This is despite suggestion
that endometrial injury induced decidulisation is more
prominent in the luteal phase of the cycle [42].
The similarities and differences between the three PIP
studies are outlined in Table 3.
Study procedures
A gynaecologist or trainee gynaecologist with experience
in performing endometrial biopsies will undertake the
endometrial biopsy and placebo procedures. Participants
may be advised to attend with a full bladder and to take
paracetamol prior to the procedure to minimise any
discomfort.
Endometrial biopsy
Participants randomised to the intervention arm of the
PIP studies will undergo an endometrial biopsy procedure,
performed using a biopsy catheter (for example, Pipelle de
Cornier, Laboratoire CCD, France).
Unless otherwise requested, the woman will lie in the
dorsal or lithotomy position and a speculum will be
Table 3 Comparison of the design of the three PIP studies
PIP-IVF PIP-UE PIP-PCOS
Standard care IVF/ICSI/embryo transfer No treatment Ovulation induction medication
(metformin, clomiphene,
Method of attempted conception IVF/ICSI/embryo transfer Intercourse Intercourse
Randomisation timing Approx. day 1 of cycle prior to
treatment cycle
Immediately prior to the
intervention
Immediately prior to the
intervention
Intervention Endometrial scratching by pipelle Endometrial scratching
by pipelle
Endometrial scratching by pipelle
Control group No procedure Placebo procedure Placebo procedure
Intervention timing Between day of the cycle prior to IVF,
until day 3 of the IVF cycle
Between days 1–12 of the
first study cycle
Between days 1–12 of the first
study cycle
Blinding Open label Single-blind (participants
are blind)
Single-blind (participants are blind)
Number of study cycles/opportunities
to conceive
One Three Three
Study diary No Yes Yes
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inserted through the cervix up to the fundus. A tenacu-
lum may be placed on the anterior lip of the cervix to
help straighten the internal os to aid delivery. The in-
ternal piston is withdrawn to create negative pressure.
The catheter is advanced to the fundus and then moved
back and forth four times, rotating 90 degrees each time,
to collect the biopsy (Fig. 1). The catheter is then re-
moved followed by the speculum. The catheter contain-
ing the biopsy sample is then discarded unless the
endometrial sample is required for another purpose.
If the pipelle is unable to be inserted into the uterus,
local anaesthetic and cervical dilation are permitted, or aFig. 1 The endometrial biopsy procedure. Image provided by Krames Staywsecond attempt may be scheduled. The procedure is to
be abandoned at the participants’ request — for example,
due to pain or discomfort — or if the operator is unable
to pass the pipelle. These participants will be retained
in the group denominator as per intention-to-treat
principles.
Placebo procedure
In PIP-PCOS and PIP-UE, women in the control arm of
the trial will undergo a placebo procedure which is de-
signed to blind participants to their allocation. If couples
who are attempting to conceive with sexual intercourse
are aware of their study allocation, they may purposelyell, 780 Township Line Road, Yardley, PA 19067, 267-685-2500)
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through behavioural changes, such as a change in sexual
frequency or timing.
For the placebo procedure the women will lie in the
dorsal or lithotomy position and a speculum will be
inserted into the vagina. The biopsy catheter will be
placed at the posterior fornix but not inserted into the
external os of the cervix. The internal piston is with-
drawn and the catheter moved and rotated slightly to
replicate the standard biopsy action. The catheter is then
removed, followed by the speculum. The catheter is then
discarded.
Participants randomised to the control group in PIP-
IVF will not undergo any procedure that is additional to
standard care.
Shortly following the procedure and before leaving the
clinic, participants will be asked to record the pain they
experienced during the procedure on a 10 cm VAS. Par-
ticipants will also be handed an information leaflet de-
tailing what to expect following an endometrial biopsy,
and told to seek medical attention and contact the study
coordinator if they experience any adverse events that
are potentially associated with the procedure, for ex-
ample, heavy bleeding or signs of infection such as foul
smelling discharge.
In PIP-IVF, participants will be contacted within one
week of the procedure and asked to report whether they
had any vaginal bleeding the day following the proced-
ure. Women in PIP-PCOS and PIP-UE will be asked to
complete a study diary for the three study cycles. In this
diary they will record the date of the procedure, whether
they had any vaginal bleeding the day following the pro-
cedure, each day that they have their period and each
time they have sexual intercourse during the on-study
period. Women will continue to complete the study
diary until their third period following the procedure or
until confirmation of a clinical pregnancy (that is, all pa-
tients have three cycles or opportunities for conception
within the on-study period). Participants should be con-
tacted at least once a month to check in and ensure they
are completing the study diary and to provide an oppor-
tunity to identify any protocol violations.
Assessment of participant blinding
The sham procedure employed in PIP-UE and PIP-
PCOS is designed to blind participants to their random-
isation allocation. The sham procedure involves placing
the pipelle in the posterior fornix and not inserting it
through the cervix or into the womb, and hence it is
expected to cause less pain on average than the inter-
ventional procedure. Although participants may not
know how much pain to expect from either procedure,
some participants may have prior expectations regarding
the anticipated degree of pain from either procedure,and this may reduce the efficacy of the blinding. For
example, women may have had previous intrauterine
procedures or read information about endometrial biopsy
on the Internet.
To assess whether participants in PIP-PCOS and PIP-
UE are truly blinded to their study allocation, they will
be asked to guess their study allocation (from the op-
tions of: pipelle procedure, placebo procedure or don’t
know) and to supply a reason to support their guess.
Participants will be randomised a second time following
the procedure to either the ‘ask early’ group or the ‘ask
late’ group. The ‘ask early’ group will be asked to guess
their allocation within one week of the procedure,
and the ‘ask late’ group will be asked to guess their
allocation at the end of the study (that is, when the
participant knows whether or not they have fallen
pregnant in the study). Participants randomised to
early will also be asked to guess again at the end of
the study, to assess whether there are changes in re-
sponse over time. Participants will be informed of
their allocation after they guess their allocation at the
end of the study.On-study period (study duration)
PIP-IVF Women in PIP-IVF who undergo embryo
transfer are usually scheduled for a serum human chori-
onic gonadotrophin test to confirm pregnancy approxi-
mately two weeks following embryo transfer (Table 1).
Women with a positive pregnancy test will be followed
up to determine clinical pregnancy by ultrasound at ap-
proximately six weeks gestation. The cycle prior to em-
bryo transfer and the embryo transfer cycle are defined
as the on-study period (Fig. 2). If the participants’ IVF
cycle or embryo transfer is delayed, the recorded out-
come will be the pregnancy result of the first embryo
transfer which takes place within three calendar months
of the expected day one of the embryo transfer cycle/day
one of stimulation injections. The expected day one of
the embryo transfer cycle is recorded at the time of
randomisation.PIP-PCOS and PIP-UE Participants in PIP-UE and
PCOS are asked to try to conceive for three cycles: the
cycle in which they undergo the study procedure and
the two following cycles. Participants remain in the
study until they either achieve a clinical pregnancy or
get their third menstrual period following the procedure.
This means that each participant has three cycles whilst
on the study where they have the opportunity to con-
ceive. For PIP-PCOS women this time frame is constant
regardless of whether the cycles are ovulatory or not.
The three study cycles are defined as the on-study
period (Fig. 3).
Fig. 2 Timing of endometrial injury in PIP-IVF in relation to the IVF cycle and the on-study period. OPU = oocyte pick-up, ET = embryo transfer,
hCG = human chorionic gonadotrophin (pregnancy) test
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The first clinical outcome assessment (clinical pregnancy)
will be done via ultrasound at approximately six weeks
gestation at the respective trial centres. Ongoing preg-
nancy will then be assessed via ultrasound on or after
12 weeks gestation. Live birth is the primary study out-
come and will be determined via correspondence with
participants, from hospital records or via outcome data
collected retrospectively at the trial centres.
Statistics
Sample size
PIP-IVF Based on the results of a Cochrane review on
endometrial injury for IVF, a difference between arms of
16 % may be expected (pooled live birth rates of 33 %
and 17 % [43]). At 90 % power and a significance level
of 5 % in a two-sided test, at least 188 women are re-
quired in each arm (376 in total). In order to power for
detection of any subgroup differences (for example,
whether endometrial injury increases live birth rate in
women undergoing frozen-thaw transfers) and assuming
an equal recruitment of fresh and frozen transfer, the re-
quired sample was doubled, raising the total number re-
quired to 752.
PIP-UE Current rates of pregnancy in women with un-
explained infertility undergoing expectant management
are approximately 3 % per cycle [44]. An expected in-
crease in pregnancy rates to 9 % in the biopsy arm mightFig. 3 Timing of endometrial injury in PIP-PCOS in relation to the on-studybe expected based on previous studies. With 3 months of
expectant management, this equates to an expected cu-
mulative difference of 25 % vs 9 % in the biopsy and sham
arms respectively. With an adjustment for live birth rates,
which are generally 19 % lower than pregnancy rates [45],
the expected difference becomes 20 % vs. 7 %. At 90 %
power and a significance level of 5 % in a two-sided test,
158 women are required in each arm (316 in total).
PIP-PCOS PIP-PCOS sample size is based on the PCOS
I trial, where a live birth rate per visit in the clomiphene
arm was 5 % for the first 3 months [46]. An increase to
12 % per cycle as per previous studies might be ex-
pected. At 90 % power and a significance level of 5 % in
a two-sided test, 126 women are required in each arm
(252 in total).
Applying a 10 % contingency in each study to account
for 1) women allocated to the biopsy group who fail to
have a biopsy due to difficulty passing the pipelle, and 2)
for participant attrition, the following numbers of partic-
ipants are required in each study: PIP-IVF = 840, PIP-
UE = 350, PIP-PCOS = 280. In the context of growing
uncertainty regarding the beneficial effects of endomet-
rial scratching, a power of 90 % was selected to reduce
the probability of a type 2 error.
Statistical analysis
Demographic and baseline data will be compared be-
tween the two groups using the chi-squared test or t-period. hCG = human chorionic gonadotrophin (pregnancy) test
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treated in an intention-to-treat manner, such that all
participants remain in the groups to which they were
randomised. If no outcome data is available for the
primary outcome of live birth, this will be imputed to
assume that women with no outcome data did not
have a live birth. Sensitivity analyses based on differ-
ent assumptions may be used for secondary analyses.
Per protocol analyses will be conducted as a second-
ary analysis.
For binary outcomes (for example, live birth), risk
ratios will be calculated with associated 95 % confidence
intervals and p values. ANOVA or logistic regression
analysis will be used for the analysis of pre-specified sub-
group effects. For continuous outcomes (such as pain),
the mean difference will be calculated and the student’s
t-test will be used.
Assessment of participant blinding will be performed
using both James’ and Bang’s blinding indices [47, 48].
All statistical analysis will be performed using STATA or
a similar statistical programme.Subgroup analyses
The following subgroup analyses are planned for the
primary outcome of live birth:PIP-UE
1. Type of embryo transfer (fresh or frozen)
2. Number of embryos transferred (single or double)
3. Number of previous embryo transfer procedures
not resulting in a clinical pregnancy (for example,
0–1, 2–4, ≥5)
4. Number of embryos transferred previously not
resulting in a clinical pregnancy (for example, 0–1,
2–4, ≥5)
5. Timing of endometrial biopsy (for example,
follicular phase: cycle prior to embryo
transfer cycle, luteal phase: cycle prior to
ET cycle, follicular phase: embryo
transfer cycle)
6. Major cause of infertility (for example, male factor,
endometriosis, ovulatory factor, unexplained, tubal
factor, other)
7. History of endometriosis (endometriosis or no
endometriosis)
8. Type of IVF (IVF or ICSI)
9. Type of stimulation protocol (for example,
long agonist, ultralong agonist, short agonist,
antagonist)
10. Duration of infertility (for example, < 2 years,
2–5 years, >5 years)
11. Stage of embryos at transfer (for example,
day 5/6 or day 2/3)PIP-PCOS
1. The type of ovulation induction medication
the participant was on when they conceived
(for example, clomiphene, letrozole, metformin,
FSH and each combination used)
2. Number of previous ovulatory ovulation induction
cycles (for example, 0–2, 3–6, >6)
3. Presence of endometriosis (endometriosis or no
endometriosis)
4. Timing of endometrial injury (for example,
during menstruation or not)PIP-UE
1. Presence of endometriosis (endometriosis or no
endometriosis)
2. Timing of endometrial injury (for example, during
menstruation or not)
3. Duration of infertility (for example, < 2 years,
2–5 years, >5 years)
For the outcome of pain during the procedure the
following subgroup analysis will be performed:
1. Previous cervical surgery (yes or no)
2. Whether a tenaculum was used during the
procedure (yes or no)
3. Whether the procedure was performed during
menstruation (yes or no).
Subgroup analyses will also be conducted to assess
whether the probability of completing the endometrial
biopsy procedure (that is, not abandoning the proced-
ure) or needing a tenaculum to complete the procedure,
is associated with the age of the woman or whether she
had previous cervical surgery.
Any subgroup analyses conducted which are not pre-
specified will be clearly stated as ad hoc and will be used
for hypothesis generating only.Study sites and recruitment
The PIP trials are international, multi-centre trials with
recruitment currently underway in a total of ten sites
across six countries, as of January 2016 (Table 4). Re-
cruitment at additional sites may commence in the fu-
ture. It is anticipated that recruitment will be completed
by mid-2017.Ethics and confidentiality
At the time of submitting this Protocol the PIP studies
had received ethical approval from: 1) Northern A Health
and Disability Ethics Committees, Ministry of Health,
New Zealand, 2) Research and Human Research Ethics
Table 4 Recruiting centres
Recruiting centre Country
Fertility Plus, Auckland New Zealand
Repromed, Auckland New Zealand
Fertility Associates, Wellington New Zealand
Fertility Associates, Christchurch New Zealand
Fertility Associates, Auckland New Zealand
Sahlgrenska University Hospital, Gothenburg Sweden
Leuven Fertility Centre, Leuven Belgium
Royal Women’s Hospital, Melbourne Australia
Medical School of Ribeirao Preto, Sao Paulo Brazil
El-Khayat Clinic, Cairo Egypt
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Australia, 3) Research Ethics Committee, Faculty of
Medicine, Cairo University, Egypt, 4) Ethics Committee of
the Hospital of the Clinical Medical College, Riberio Preto,
Brazil, 5) Institutional Ethics Committee, Queensland
Fertility Group, Australia, 6) Regional ethical review board
in Gothenburg, 7) Committee Medical Ethics, UZ KU
Leuven/Research. All relevant ethics and locality approvals
have been obtained prior to recruitment commencing at
each participating site, and will be obtained prior to re-
cruitment at any site that starts recruiting in the future.
All patient health information will be treated confiden-
tially. Investigators and study staff will only have access
to health information about participants recruited at
their clinic; for example, site A will not have access to
patient data from site B.
The PIP studies will be conducted according to the
Principles of Good Clinical Practice as defined in the
Medicines for Human Use (Clinical Trials) Amended
Regulations 2006.
Roles and responsibilities
The Chief Principal Investigator is Professor Cynthia
Farquhar, based at Fertility Plus, Auckland District
Health Board, which is the coordinating site for the PIP
studies. The coordinating centre is responsible for moni-
toring recruitment rates, communicating protocol changes
to participants, investigators and clinical trial registries,
and conducting data quality and completeness auditing.
Together the Chief Investigator and at least one investiga-
tor from each recruiting site form the Steering Committee
for the PIP studies. The role of this committee is to
consider matters relating to protocol amendments and
recruitment strategies. The results of the PIP studies will
be published in peer-reviewed journals within 12 months
of trial closure, and be uploaded to the trial registration
website, as per WHO recommendations [49]. Authorship
of any resulting publications will be governed by the
Steering Committee. The results will also be madeavailable to trial participants who indicated they wished to
receive a trial report on their consent form.
The PIP trials are investigator initiated studies, and no
study sponsor is applicable. Provisions relating to com-
pensation for any adverse outcome associated with trial
participation are organised on a case-by-case basis at the
recruiting site.
Participant withdrawal
Participants are free to withdraw from the study at any
time. Prior to randomisation, participants will give their
consent that any information collected about them, up
to the point that they withdraw, can still be processed
and analysed in the study. If a participant chooses to
withdraw from the study, from this point onwards no
further study procedures may occur and no further data
may be collected. There is no replacement of participants
who withdraw, as a contingency for this has been built
into the sample size calculations.
Protocol violations
Participants who do not follow the planned protocol are
considered to have a protocol violation. This includes,
for example, those for whom an endometrial biopsy is
not successful or those who undergo an additional fertility
treatment. The nature of the protocol violation will be
documented for each participant. Participants who with-
draw or who have a protocol violation will remain in the
study denominator as per intention-to-treat principles.
Interim analyses and data and safety monitoring
No interim analyses will be conducted. No data safety
monitoring committee will be established.
Adverse events are defined as any untoward medical
occurrence in a randomised patient regardless of its
causal relationship to study treatment. Provision has
been made for actively recording adverse events which
are expected, for example, miscarriage, multiple gesta-
tions and pain during the procedure. Additionally, due
to concern regarding the possible influence of endomet-
rial disturbance on the implantation site of an embryo,
the location of the placenta will be recorded following
live birth.
Participants will be asked to report any other adverse
events to the study coordinator when they occur; these
will not be actively recorded. All adverse events that
occur during the study period will be documented on a
designated data form. It should be noted that endomet-
rial biopsy is a safe and well-tolerated procedure which
is routinely performed in women in whom uterine path-
ology is suspected, for example, women with menorrhagia.
Adverse events and complications related to this proced-
ure include infection, haemorrhage and perforation of the
uterus, but these are rare [6, 7].
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Data will be entered and stored electronically on the
secure online PIP studies data collection and randomisa-
tion system. This database has inbuilt logical and valid-
ation, such that only impossible values are not allowed
and to avoid cases of missing data where it is not applic-
able. Some information will be retrieved from source
documents such as patient notes, and other clinical in-
formation may be entered directly into the PIP database.
Individual logins will be issued to each person, and
individuals will only have access to data regarding partici-
pants who are recruited at their clinic.
Researcher assistants, doctors and nurses involved in
the PIP study will be responsible for the data collection
at each site. Study data will be collected at numerous
time points during the study journey (Table 1, Table 2).
Data may be collected directly for the purposes of the
study, for example, the pain score as measured following
the procedure or the intercourse frequency as recorded
in the diary, or indirectly via the patient records which
are routinely recorded for their treatment purposes (for
example, date of embryo transfer).Data storage
The PIP database is hosted by the University of Auckland,
and will run on a dedicated server at the University of
Auckland server farm, behind firewalls with daily backup
and 128-bit SSL encryption. The University of Auckland
will retain ownership of the PIP studies trial data. Data
will be stored securely on the PIP database for 10 years
following the completion of the study, after which time it
will be disposed.Discussion
IVF is the leading treatment for subfertility; however, the
success rate remains modest at approximately 30 % per
cycle [2, 3]. Endometrial scratching is currently being
suggested as a technique to improve the probability of
embryo implantation and therefore pregnancy in women
undergoing IVF. However, due to the potential for bias
associated with many of the available studies, the pres-
ence of a therapeutic effect remains uncertain.
The PIP trials are designed to address the gaps in the
utility of endometrial scratching as a treatment for sub-
fertility in three different populations. If the beneficial
effect of this intervention can be confirmed in these set-
tings, endometrial scratching will provide a cost-effective
method for helping women and couples to conceive. On
the other hand, if endometrial scratching is found to
have no effect, or to be detrimental to the probability of
conception, the use of this procedure can be abandoned
amongst the clinics and doctors who are recommending
this procedure to their patients.Trial status
Ongoing (recruitment commenced June 2014).
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